Merck Serono names three grant winners

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MERCK SERONO awarded its first Grant for Oncology Innovation, who will receive grants totaling EUR 1 million. The grant supports researchers focused on personalized treatment of solid tumors.

The 2014 winners were formally announced at the annual meeting of the European Society for Medical Oncology in Madrid. They are:

Clara Montagut, of Hospital del Mar, in Barcelona, Spain; for proposed research on ultra-selection and molecular monitoring of CRC patients treated with anti-EGFR therapy using NGS platforms and serial liquid biopsies.

Stefan Sleijfer, of the Erasmus MC Cancer Institute, in Rotterdam, Netherlands; for proposed research on non-invasive monitoring of breast cancer therapy using cell-free tumor DNA in blood.

Ulrich Güller, of Cantonal Hospital, in St. Gallen, Switzerland; for a prospective, double-blinded, placebo-controlled, phase III randomized trial of adjuvant aspirin treatment in PIK3CA mutated colon cancer patients.

Table of Contents

YOU MAY BE INTERESTED IN

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login